Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Quan Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
The average size of a deal this fund participated in
Portfolio companies 19
Rounds per year 5.00
Lead investments 4
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 4
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Biopharma
  • Medical

In 2017 was created Quan Capital, which is appeared as VC. The venture was found in Asia in China. The main office of represented VC is situated in the Shanghai.

The overall number of key employees were 3.

Among the most popular portfolio startups of the fund, we may highlight ARMO BioSciences, Centrexion, Tempest Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Biotechnology, Mobile Apps.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Quan Capital, startups are often financed by OrbiMed, Kleiner Perkins, DAG Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Takeda Ventures, Qiming Venture Partners. In the next rounds fund is usually obtained by EFung Capital.

The average startup value when the investment from Quan Capital is 100-500 millions dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 investment rounds annually. This Quan Capital works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2019. Considering the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Quan Capital:
Typical Co-investors
Quan Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Quan Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
BayStartUP Bavaria, Germany, Nuremberg
Beechtree Capital New York, New York, United States
Binhai China, Guangdong, Guangzhou
Blackstone Technology Group Massachusetts, United States, Worcester
Chief Scientist -
Eatable Adventures Community of Madrid, Madrid, Spain
John E. Fetzer Memorial Trust Mississippi, United States, Vicksburg
Liquidity Capital New York, New York, United States
Millennium Network New York, New York, United States
NDI Healthcare Fund Cleveland, Ohio, United States
Netmarble Seoul, Seoul-t'ukpyolsi, South Korea
Pablo Capital -
Penny Black New York, New York, United States
POMP France, Ile-de-France, Paris
Shandong Best Power Investment China, Jinan, Shandong
Stoic Capital Brooklyn, New York, United States
Strategic Aerospace and Defence Initiative Canada, Ontario, Ottawa
Weston Presidio Capital Boston, Massachusetts, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Oricell Therapeutics

Health Care
Product Research
$120M01 Aug 2022 Shanghai, Shanghai, China

Yuanyin Bio

$43M20 Jun 2022 Haidian, Beijing, China

Innoforce Pharmaceuticals

Health Care
$57M06 Dec 2021 Hangzhou, Zhejiang, China

Yuanyin Bio

$15M29 Nov 2021 Haidian, Beijing, China

Walking Fish Therapeutics

Life Science
$50M13 Sep 2021 San Francisco, California, United States

Interius BioTherapeutics

Health Care
$76M18 May 2021 Philadelphia, Pennsylvania, United States

Life Science
$60M09 May 2021 Shanghai, China

Innoforce Pharmaceuticals

Health Care
$96M22 Mar 2021 Hangzhou, Zhejiang, China

Design Therapeutics

Life Science
$125M27 Jan 2021 California, United States
Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases

– Walking Fish Therapeutics, a leader in B cell engineering, announced the close of $50M Series A financing— led by Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
– Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.

Interius BioTherapeutics Raises $76M in Series A Financing

– Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing.
– The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Quan Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: